Phase I/II Study of the CDK2/9 Inhibitor Fadraciclib in Combination with Chemotherapy in Children with Advanced Malignancies: Arm K of the AcSé-ESMART Trial.
- DOI
- 10.1007/s11523-026-01208-1
- Published
- 2026 Mar
- Container
- Targeted oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1007/s11523-026-01208-1,
title = {Phase I/II Study of the CDK2/9 Inhibitor Fadraciclib in Combination with Chemotherapy in Children with Advanced Malignancies: Arm K of the AcSé-ESMART Trial.},
author = {Rubio-San-Simón A and Marshall LV and Karamouza E and André N and Abbou S and Rubino J and Nebchi S and Aerts I and Thebaud E and Brisset C and Ducassou S and Le Teuff G and Geoerger B},
year = {2026},
journal = {Targeted oncology},
doi = {10.1007/s11523-026-01208-1},
url = {https://doi.org/10.1007/s11523-026-01208-1}
}RIS
TY - JOUR TI - Phase I/II Study of the CDK2/9 Inhibitor Fadraciclib in Combination with Chemotherapy in Children with Advanced Malignancies: Arm K of the AcSé-ESMART Trial. AU - Rubio-San-Simón A AU - Marshall LV AU - Karamouza E AU - André N AU - Abbou S AU - Rubino J AU - Nebchi S AU - Aerts I AU - Thebaud E AU - Brisset C AU - Ducassou S AU - Le Teuff G AU - Geoerger B PY - 2026 JO - Targeted oncology DO - 10.1007/s11523-026-01208-1 UR - https://doi.org/10.1007/s11523-026-01208-1 ER -
APA
A, R., LV, M., E, K., N, A., S, A., J, R., S, N., I, A., E, T., C, B., S, D., G, L. T., & B, G. (2026). Phase I/II Study of the CDK2/9 Inhibitor Fadraciclib in Combination with Chemotherapy in Children with Advanced Malignancies: Arm K of the AcSé-ESMART Trial.. Targeted oncology. https://doi.org/10.1007/s11523-026-01208-1
Source records
- pubmed · retrieved 2026-09-27T00:18:40.321Z